Advisor Group’s Forte Biosciences FBRX Stock Holding History

Advisor Group’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-4	Closed	-$20K	–	4962
2018 Q1	$20K	Buy	4 +1	+33%	+$4.63K	﹤0.01%	3673
2017 Q4	$10K	Buy	+3	New	+$12K	﹤0.01%	4079

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Advisor Group's FBRX Position: Q2 2018 in Review

Advisor Group sold out of Forte Biosciences (FBRX) in Q2 2018, closing a stake of 4 shares — an estimated $20K sold.

Advisor Group first reported a position in FBRX in Q4 2017 and held it in 2 quarters. The position peaked at $20K in Q1 2018. 61 funds tracked by Wall St. Rank hold FBRX as of Q2 2018.

Advisor Group reported no remaining Forte Biosciences position as of Q2 2018 after selling out during the quarter.
Advisor Group sold 4 Forte Biosciences shares in Q2 2018, an estimated $20K.
Advisor Group first reported a position in Forte Biosciences in Q4 2017 and held it in 2 quarters.
Advisor Group's Forte Biosciences position peaked at $20K in Q1 2018.
61 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2018.

Based on Advisor Group's 13F filing for Q2 2018, filed 13 Aug 2018.